中国创新药企亚盛医药(HK06855,股价41.65港元,市值131.3亿港元),正“叫板”跨国药企艾伯维的明星产品“维奈克拉”。 11月17日,亚盛医药宣布,公司自主研发的新型选择性Bcl-2抑制剂APG-2575的新药上市申请已获国家药品监督管理局药品审评中心受理,并拟纳入优先审评,该药物用于治疗难治或复发性(r/r)慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者。这是首个在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.